Literature DB >> 32165103

The blind men and the elephant: Systematic review of systematic reviews of cannabis use related health harms.

E Campeny1, H López-Pelayo2, D Nutt3, C Blithikioti2, C Oliveras2, L Nuño2, R Maldonado4, G Florez5, F Arias6, S Fernández-Artamendi7, J R Villalbí8, J Sellarès2, M Ballbè9, J Rehm10, M M Balcells-Olivero2, A Gual2.   

Abstract

Cannabis is the third most used psychoactive substance worldwide. The legal status of cannabis is changing in many Western countries, while we have very limited knowledge of the public health impact of cannabis-related harms. There is a need for a summary of the evidence of harms and risks attributed to cannabis use, in order to inform the definition of cannabis risky use. We have conducted a systematic review of systematic reviews, aiming to define cannabis-related harms. We included systematic reviews published until July 2018 from six different databases and following the PRISMA guidelines. To assess study quality we applied the AMSTAR 2 tool. A total of 44 systematic reviews, including 1,053 different studies, were eligible for inclusion. Harm was categorized in three dimensions: mental health, somatic harm and physical injury (including mortality). Evidence shows a clear association between cannabis use and psychosis, affective disorders, anxiety, sleep disorders, cognitive failures, respiratory adverse events, cancer, cardiovascular outcomes, and gastrointestinal disorders. Moreover, cannabis use is a risk factor for motor vehicle collision, suicidal behavior and partner and child violence. Cannabis use is a risk factor for several medical conditions and negative social consequences. There is still little data on the dose-dependency of these effects; evidence that is essential in order to define, from a public health perspective, what can be considered risky use of cannabis. This definition should be based on quantitative and qualitative criteria that informs and permits the evaluation of current approaches to a regulated cannabis market.
Copyright © 2020 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Cannabis; Harms; Mental health; Organic; Risks; injury

Year:  2020        PMID: 32165103     DOI: 10.1016/j.euroneuro.2020.02.003

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  22 in total

1.  Olfactory Neuroepithelium Cells from Cannabis Users Display Alterations to the Cytoskeleton and to Markers of Adhesion, Proliferation and Apoptosis.

Authors:  Alejandra Delgado-Sequera; María Hidalgo-Figueroa; Marta Barrera-Conde; Mª Carmen Duran-Ruiz; Carmen Castro; Cristina Fernández-Avilés; Rafael de la Torre; Ismael Sánchez-Gomar; Víctor Pérez; Noelia Geribaldi-Doldán; Patricia Robledo; Esther Berrocoso
Journal:  Mol Neurobiol       Date:  2020-11-25       Impact factor: 5.590

2.  Impact of the policy environment on substance use among sexual minority women.

Authors:  Laurie A Drabble; Cat Munroe; Amy A Mericle; Sarah Zollweg; Karen F Trocki; Katherine J Karriker-Jaffe
Journal:  Drug Alcohol Depend Rep       Date:  2022-04-29

3.  Geospatiotemporal and causal inference study of cannabis and other drugs as risk factors for female breast cancer USA 2003-2017.

Authors:  Albert Stuart Reece; Gary Kenneth Hulse
Journal:  Environ Epigenet       Date:  2022-03-01

4.  Associations of Healthcare Service Utilization With Cannabis Use Status, Use Reasons, and Use Characteristics Among Those Age 50 and Older.

Authors:  Namkee G Choi; Diana M DiNitto; C Nathan Marti; Bryan Y Choi
Journal:  J Appl Gerontol       Date:  2022-02-25

Review 5.  The Impact of Cannabidiol on Human Brain Function: A Systematic Review.

Authors:  Albert Batalla; Julian Bos; Amber Postma; Matthijs G Bossong
Journal:  Front Pharmacol       Date:  2021-01-21       Impact factor: 5.810

Review 6.  Marijuana: A systems-based primer of adverse effects associated with use and an overview of its therapeutic utility.

Authors:  Asim Kichloo; Michael Albosta; Michael Aljadah; Zain El-Amir; Ghazaleh Goldar; Muhammed Zatmar Khan; Dushyant Singh Dahiya; Srilakshmi Vallabhaneni; Farah Wani; Jagmeet Singh
Journal:  SAGE Open Med       Date:  2021-03-09

7.  International Association for the Study of Pain Presidential Task Force on Cannabis and Cannabinoid Analgesia: research agenda on the use of cannabinoids, cannabis, and cannabis-based medicines for pain management.

Authors:  Simon Haroutounian; Lars Arendt-Nielsen; Joletta Belton; Fiona M Blyth; Louisa Degenhardt; Marta Di Forti; Christopher Eccleston; David P Finn; Nanna B Finnerup; Emma Fisher; Alexandra E Fogarty; Ian Gilron; Andrea G Hohmann; Eija Kalso; Elliot Krane; Mohammed Mohiuddin; R Andrew Moore; Michael Rowbotham; Nadia Soliman; Mark Wallace; Nantthasorn Zinboonyahgoon; Andrew S C Rice
Journal:  Pain       Date:  2021-07-01       Impact factor: 6.961

8.  Supporting Future Cannabis Policy - Developing a Standard Joint Unit: A Brief Back-Casting Exercise.

Authors:  Hugo López-Pelayo; Silvia Matrai; Mercè Balcells-Olivero; Eugènia Campeny; Fleur Braddick; Matthijs G Bossong; Olga S Cruz; Paolo Deluca; Geert Dom; Daniel Feingold; Tom P Freeman; Pablo Guzman; Chandni Hindocha; Brian C Kelly; Nienke Liebregts; Valentina Lorenzetti; Jakob Manthey; João Matias; Clara Oliveras; Maria Teresa Pons; Jürgen Rehm; Moritz Rosenkranz; Zoe Swithenbank; Luc van Deurse; Julian Vicente; Mike Vuolo; Marcin Wojnar; Antoni Gual
Journal:  Front Psychiatry       Date:  2021-05-20       Impact factor: 4.157

9.  "The post-COVID era": challenges in the treatment of substance use disorder (SUD) after the pandemic.

Authors:  Hugo López-Pelayo; Henri-Jean Aubin; Colin Drummond; Geert Dom; Francisco Pascual; Jürgen Rehm; Richard Saitz; Emanuele Scafato; Antoni Gual
Journal:  BMC Med       Date:  2020-07-31       Impact factor: 8.775

Review 10.  Cannabis Legalization and Acute Harm From High Potency Cannabis Products: A Narrative Review and Recommendations for Public Health.

Authors:  Justin Matheson; Bernard Le Foll
Journal:  Front Psychiatry       Date:  2020-09-23       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.